Brief: Genmab To Buy Merus For USD 8.0 Billion
Sept 29 (Reuters) - Genmab A/S GMAB.CO: GENMAB TO ACQUIRE MERUS, EXPANDING LATE-STAGE PIPELINE AND ACCELERATING INTO A WHOLLY OWNED MODEL GENMAB A/S - TO BUY MERUS FOR USD 8.0 BILLION GENMAB A/S - DEAL EXPECTED TO BE ACCRETIVE TO EBITDA BY 2029 GENMAB A/S - USD 97.00 PER SHARE REPRESENTS 41% PREMIUM OVER CLOSING PRICE Source text: ID:nGNXbNxYqj Further company coverage: GMAB.CO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab